Low serum complements in idiopathic inflammatory myositis: clinical features and impact on the prognosis

References

• Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol. 2017;69(12):2271–2282. doi: 10.1002/art.40320.
   PubMed Web of Science ®Google Scholar
• Wang H, Lv J, He J, et al. The prevalence and effects of treatments of rapidly progressive interstitial lung disease of dermatomyositis/polymyositis adults: a systematic review and meta-analysis. Autoimmun Rev. 2023;22(8):103335. doi: 10.1016/j.autrev.2023.103335.
   PubMed Web of Science ®Google Scholar
• Fairley JL, Wicks I, Peters S, et al. Defining cardiac involvement in idiopathic inflammatory myopathies: a systematic review. Rheumatology (Oxford). 2021;61(1):103–120. doi: 10.1093/rheumatology/keab573.
   PubMed Web of Science ®Google Scholar
• Lundberg IE, Fujimoto M, Vencovsky J, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021;7(1):86. doi: 10.1038/s41572-021-00321-x.
   PubMedGoogle Scholar
• Koga T, Fujikawa K, Horai Y, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford). 2012;51(7):1278–1284. doi: 10.1093/rheumatology/ker518.
   PubMed Web of Science ®Google Scholar
• Sato S, Masui K, Nishina N, et al. Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients. Rheumatology (Oxford). 2018;57(7):1212–1221. doi: 10.1093/rheumatology/key060.
   PubMed Web of Science ®Google Scholar
• Tanizawa K, Handa T, Nakashima R, et al. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies. Respir Med. 2017;127:57–64. doi: 10.1016/j.rmed.2017.04.007.
   PubMed Web of Science ®Google Scholar
• Day JA, Limaye V. Immune-mediated necrotising myopathy: a critical review of current concepts. Semin Arthritis Rheum. 2019;49(3):420–429. doi: 10.1016/j.semarthrit.2019.04.002.
   PubMed Web of Science ®Google Scholar
• De Bleecker JL, De Paepe B, Aronica E, et al. 205th ENMC International Workshop: pathology diagnosis of idiopathic inflammatory myopathies part II 28-30 March 2014, Naarden, The Netherlands. Neuromuscul Disord. 2015;25(3):268–272. doi: 10.1016/j.nmd.2014.12.001.
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362(9388):971–982. doi: 10.1016/s0140-6736(03)14368-1.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Review: an update on inflammatory and autoimmune myopathies. Neuropathol Appl Neurobiol. 2011;37(3):226–242. doi: 10.1111/j.1365-2990.2010.01153.x.
   PubMed Web of Science ®Google Scholar
• Cavalli S, Lonati PA, Gerosa M, et al. Beyond systemic lupus erythematosus and anti-phospholipid syndrome: the relevance of complement from pathogenesis to pregnancy outcome in other systemic rheumatologic diseases. Front Pharmacol. 2022;13:841785. doi: 10.3389/fphar.2022.841785.
   PubMed Web of Science ®Google Scholar
• Behan WM, Behan PO. Complement abnormalities in polymyositis. J Neurol Sci. 1977;34(2):241–246. doi: 10.1016/0022-510x(77)90072-7.
   PubMed Web of Science ®Google Scholar
• Rider LG, Koziol D, Giannini EH, et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken). 2010;62(4):465–472. doi: 10.1002/acr.20035.
   PubMed Web of Science ®Google Scholar
• Shimojima Y, Ishii W, Matsuda M, et al. Coadministration of cyclosporin a with prednisolone in acute interstitial pneumonia complicating polymyositis/dermatomyositis. Clin Med Insights Arthritis Musculoskelet Disord. 2012;5:43–52. doi: 10.4137/cmamd.S9398.
   PubMedGoogle Scholar
• Shimojima Y, Ishii W, Matsuda M, et al. Effective use of calcineurin inhibitor in combination therapy for interstitial lung disease in patients with dermatomyositis and polymyositis. J Clin Rheumatol. 2017;23(2):87–93. doi: 10.1097/rhu.0000000000000487.
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725–1725. doi: 10.1002/1529-0131(199709)40:9<1725::aid-art29>3.0.co;2-y.
   PubMed Web of Science ®Google Scholar
• Petri M, Orbai A-M, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–2686. doi: 10.1002/art.34473.
   PubMed Web of Science ®Google Scholar
• Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151–1159. doi: 10.1136/annrheumdis-2018-214819.
   PubMed Web of Science ®Google Scholar
• Cao H, Huang J, Chang J, et al. Predictors of progression in idiopathic inflammatory myopathies with interstitial lung disease. J Transl Int Med. 2023;11(1):46–56. doi: 10.2478/jtim-2022-0029.
   PubMed Web of Science ®Google Scholar
• Behan WMH, Barkas T, Behan PO. Detection of immune complexes in polymyositis. Acta Neurol Scand. 1982;65(4):320–334. doi: 10.1111/j.1600-0404.1982.tb03089.x.
   PubMed Web of Science ®Google Scholar
• Bitencourt N, Solow EB, Wright T, et al. Inflammatory myositis in systemic lupus erythematosus. Lupus. 2020;29(7):776–781. doi: 10.1177/0961203320918021.
   PubMed Web of Science ®Google Scholar
• Roved J, Westerdahl H, Hasselquist D. Sex differences in immune responses: hormonal effects, antagonistic selection, and evolutionary consequences. Horm Behav. 2017;88:95–105. doi: 10.1016/j.yhbeh.2016.11.017.
   PubMed Web of Science ®Google Scholar
• Troldborg A, Hansen A, Hansen SW, et al. Lectin complement pathway proteins in healthy individuals. Clin Exp Immunol. 2017;188(1):138–147. doi: 10.1111/cei.12909.
   PubMed Web of Science ®Google Scholar
• Gaya da Costa M, Poppelaars F, van Kooten C, et al. Age and sex-associated changes of complement activity and complement levels in a healthy Caucasian population. Front Immunol. 2018;9:2664. doi: 10.3389/fimmu.2018.02664.
   PubMed Web of Science ®Google Scholar
• Tomimitsu H, Ohta A, Nagai M, et al. Epidemiologic analysis of the clinical features of Japanese patients with polymyositis and dermatomyositis. Mod Rheumatol. 2016;26(3):398–402. doi: 10.3109/14397595.2015.1091137.
   PubMed Web of Science ®Google Scholar
• Giefing-Kröll C, Berger P, Lepperdinger G, et al. How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Aging Cell. 2015;14(3):309–321. doi: 10.1111/acel.12326.
   PubMed Web of Science ®Google Scholar
• Dunkelberger JR, Song W-C. Complement and its role in innate and adaptive immune responses. Cell Res. 2010;20(1):34–50. doi: 10.1038/cr.2009.139.
   PubMed Web of Science ®Google Scholar
• Holers VM. Complement and its receptors: new insights into human disease. Annu Rev Immunol. 2014;32(1):433–459. doi: 10.1146/annurev-immunol-032713-120154.
   PubMed Web of Science ®Google Scholar
• Bosmann M, Ward PA. Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis. Adv Exp Med Biol. 2012;946:147–159. doi: 10.1007/978-1-4614-0106-3_9.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies. Nat Clin Pract Rheumatol. 2006;2(4):219–227. doi: 10.1038/ncprheum0140.
   PubMedGoogle Scholar
• Qiu Y, Feng X, Liu C, et al. Proteomic profiling identifies SPP1 associated with rapidly progressive interstitial lung disease in anti-MDA5-positive dermatomyositis. Arthritis Res Ther. 2024;26(1):9. doi: 10.1186/s13075-023-03243-z.
   PubMed Web of Science ®Google Scholar
• Zaizen Y, Okamoto M, Azuma K, et al. Enhanced immune complex formation in the lungs of patients with dermatomyositis. Respir Res. 2023;24(1):86. doi: 10.1186/s12931-023-02362-0.
   PubMed Web of Science ®Google Scholar
• Prohászka Z, Kirschfink M, Frazer-Abel A. Complement analysis in the era of targeted therapeutics. Mol Immunol. 2018;102:84–88. doi: 10.1016/j.molimm.2018.06.001.
   PubMed Web of Science ®Google Scholar
• Coss SL, Zhou D, Chua GT, et al. The complement system and human autoimmune diseases. J Autoimmun. 2023;137:102979. doi: 10.1016/j.jaut.2022.102979.
   PubMed Web of Science ®Google Scholar
• Takamatsu R, Shimojima Y, Kishida D, et al. The impact of normal serum complement levels on the disease classification and clinical characteristics in systemic lupus erythematosus. Adv Rheumatol. 2022;62(1):49. doi: 10.1186/s42358-022-00283-y.
   PubMedGoogle Scholar
• Pisetsky DS, Lipsky PE. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nat Rev Rheumatol. 2020;16(10):565–579. doi: 10.1038/s41584-020-0480-7.
   PubMed Web of Science ®Google Scholar
• Deshayes S, Aouba A, Khoy K, et al. Hypocomplementemia is associated with worse renal survival in ANCA-positive granulomatosis with polyangiitis and microscopic polyangiitis. PLoS One. 2018;13(4):e0195680. doi: 10.1371/journal.pone.0195680.
   PubMed Web of Science ®Google Scholar
• Crnogorac M, Horvatic I, Kacinari P, et al. Serum C3 complement levels in ANCA associated vasculitis at diagnosis is a predictor of patient and renal outcome. J Nephrol. 2018;31(2):257–262. doi: 10.1007/s40620-017-0445-3.
   PubMed Web of Science ®Google Scholar
• García L, Pena CE, Maldonado R, et al. Increased renal damage in hypocomplementemic patients with ANCA-associated vasculitis: retrospective cohort study. Clin Rheumatol. 2019;38(10):2819–2824. doi: 10.1007/s10067-019-04636-9.
   PubMed Web of Science ®Google Scholar
• Chalkia A, Thomas K, Giannou P, et al. Hypocomplementemia is associated with more severe renal disease and worse renal outcomes in patients with ANCA-associated vasculitis: a retrospective cohort study. Ren Fail. 2020;42(1):845–852. doi: 10.1080/0886022x.2020.1803086.
   PubMed Web of Science ®Google Scholar
• Hakroush S, Tampe D, Korsten P, et al. Complement components C3 and C4 indicate vasculitis manifestations to distinct renal compartments in ANCA-associated glomerulonephritis. Int J Mol Sci. 2021;22(12):6588. doi: 10.3390/ijms22126588.
   PubMed Web of Science ®Google Scholar
• Nomura S, Shimojima Y, Ichikawa T, et al. Immunopathological features of myopathy associated with small-to-medium-sized vessel vasculitis and differences from autoimmune myositis. Clin Exp Rheumatol. 2024;42(4):786–794. doi: 10.55563/clinexprheumatol/hpoapl.
   PubMedGoogle Scholar
• Motegi SI, Sekiguchi A, Toki S, et al. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease. Eur J Dermatol. 2019;29(5):511–517. doi: 10.1684/ejd.2019.3634.
   PubMed Web of Science ®Google Scholar
• Rehwinkel J, Gack MU. RIG-I-like receptors: their regulation and roles in RNA sensing. Nat Rev Immunol. 2020;20(9):537–551. doi: 10.1038/s41577-020-0288-3.
   PubMed Web of Science ®Google Scholar
• He C, Li W, Xie Q, et al. Rituximab in the treatment of interstitial lung diseases related to anti-melanoma differentiation-associated gene 5 dermatomyositis: a systematic review. Front Immunol. 2021;12:820163. doi: 10.3389/fimmu.2021.820163.
   PubMed Web of Science ®Google Scholar